Patents by Inventor Joseph P. Dougherty
Joseph P. Dougherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9017935Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.Type: GrantFiled: July 17, 2012Date of Patent: April 28, 2015Assignee: University of Medicine and Dentistry of New JerseyInventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie Pacchia
-
Publication number: 20130040385Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.Type: ApplicationFiled: July 17, 2012Publication date: February 14, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia
-
Patent number: 8247167Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.Type: GrantFiled: November 27, 2006Date of Patent: August 21, 2012Assignee: University of Medicine and Dentistry of New JerseyInventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia
-
Publication number: 20090305227Abstract: Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.Type: ApplicationFiled: November 27, 2006Publication date: December 10, 2009Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Joseph P. Dougherty, Sofiya Micheva-Viteva, Stuart W. Peltz, Yacov Ron, Annmarie L. Pacchia
-
Patent number: 7198909Abstract: A long-lived, myeloid-committed stem cell population is disclosed. Also disclosed are methods and compositions for targeting this population with retrovirus vectors in gene therapy protocols for correcting congenital disorders of myeloid system and for potentiating immune responses to defined tumor and viral antigens.Type: GrantFiled: October 29, 1999Date of Patent: April 3, 2007Assignee: University of Medicine & Dentistry of New JerseyInventors: Yacov Ron, Joseph P. Dougherty, Chiann-Chyi Chen
-
Patent number: 6613569Abstract: Novel packaging cell lines for production of lentiviral vectors are disclosed. The cell lines utilize an ecdysone-inducible system for virus production, thereby avoiding the cytotoxic effect of unregulated expression of certain envelope proteins and lentiviral proteins. Various embodiments of the cell lines are disclosed, which are suitable for different purposes that range from in vitro screening assays to gene therapy in vivo.Type: GrantFiled: March 5, 2002Date of Patent: September 2, 2003Assignee: University of Medicine and Dentistry of New JerseyInventors: Joseph P Dougherty, Martin E Adelson, Malvika Kaul, AnnMarie L Pacchia, Yacov Ron
-
Patent number: 6376393Abstract: A method for making an anisotropic dielectric layer includes the steps of: forming a fluid layer comprising a plurality of magnetizable particles, for example, in a fluid capable of solidifying to fix the configuration of the magnetizable particles in a dielectric matrix; aligning the magnetizable particles of the fluid layer in a predetermined configuration by applying a magnetic field thereto; and fixing the aligned magnetizable particles in the predetermined configuration within the dielectric matrix by solidifying the fluid. In one particularly advantageous application, the fluid layer is coated onto a surface portion of an integrated circuit, such as a fingerprint sensor, to provide mechanical protection without effecting the image resolution.Type: GrantFiled: December 31, 1998Date of Patent: April 23, 2002Assignee: Harris CorporationInventors: Mike Newton, Joseph P. Dougherty, Else Breval, Maria Klimkiewicz, Yi Ton Shi, Dean Arakaki
-
Patent number: 6169049Abstract: Hydrothermal BaTiO3 crystallites were coated with Bismuth solutions prepared from Bismuth metal-organics and anhydrous solvents. The Bismuth metal-organics were Bi 2-ethylhexanoate and Bi-neodecanoate. Bismuth oxide was also used as a comparison to the Bismuth solutions. BaTiO3 ceramics with either 3.0 wt % equivalent Bismuth oxide or 5.0 wt % equivalent Bismuth oxide were made by sintering the compacts between 700° C. and 1000° C. BaTiO3 ceramics that were coated by Bi-neodecanoate densified >90% theoretical as low as 800° C. for 3.0 wt % equivalent Bi2O3. Average grain sizes of 0.2-0.4 &mgr;m were observed for Bi-coated BaTiO3 ceramics, for sintering temperatures below 950° C. Dielectric K versus temperature measurements of Bismuth-coated BaTiO3 ceramics, sintered in the lower temperature ranges, showed consistently superior dielectric characteristics.Type: GrantFiled: April 28, 1997Date of Patent: January 2, 2001Inventors: John P. Witham, Clive A. Randall, Umesh Kumar, Ulagaraj Selvaraj, Sea-Fue Wang, Joseph P. Dougherty
-
Patent number: 6069249Abstract: Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.Type: GrantFiled: May 19, 1999Date of Patent: May 30, 2000Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella
-
Patent number: 6043230Abstract: Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.Type: GrantFiled: May 19, 1999Date of Patent: March 28, 2000Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella
-
Patent number: 6022714Abstract: Compositions and methods for selectively linking a polynucleotide through its 5' or 3' end to one or more preselected materials such as insoluble matrices, solid supports, proteins, small molecular or labels are disclosed. Use of these compositions and methods in the production of diagnostic and affinity reagents are also disclosed.Type: GrantFiled: December 19, 1995Date of Patent: February 8, 2000Assignee: Genetics InstituteInventors: Eugene L. Brown, Joseph P. Dougherty, Mary Collins
-
Patent number: 5993895Abstract: A method for densifying a dielectric antiferroelectric material includes the steps of adding a compound which includes lithium to the dielectric material to create a mixture thereof. Thereafter, the mixture is heated to a temperature of not greater than about 1100.degree. C. for a predetermined period to densify the mixture. It is preferred that the lithium compound be a lithium salt and that the dielectric material comprise a PLZT composition.Type: GrantFiled: October 10, 1997Date of Patent: November 30, 1999Assignee: The Penn State Research FoundationInventors: Sei-Joo Jang, Joseph P. Dougherty, Wesley Hackenberger, MingFang Song, Steven Perini, Beth Jones
-
Patent number: 5977089Abstract: Compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.Type: GrantFiled: November 6, 1998Date of Patent: November 2, 1999Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella
-
Patent number: 5922695Abstract: Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.Type: GrantFiled: July 25, 1997Date of Patent: July 13, 1999Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella
-
Patent number: 5728138Abstract: A cardiac defibrillator includes a multilayer capacitor with a plurality of conductive electrodes and interspersed dielectric layers, each dielectric layer composed of constituents which cause it to exhibit an antiferroelectric phase. The constituents of each dielectric layer are such as to cause each layer to exhibit plural ferroelectric phases. The defibrillator includes a charging circuit for applying to the capacitor an electric field across each dielectric layer which causes a transition thereof through the plural ferroelectric phases. PLZT is the preferred dielectric material, at constituent values which cause the material to lie within the antiferroelectric phase and to exhibit plural ferroelectric phases.Type: GrantFiled: July 31, 1996Date of Patent: March 17, 1998Assignee: The Penn State Research FoundationInventors: Joseph P. Dougherty, Kamau Wa Gachigi, Thomas R. Shrout, Sei-Joo Jang, Clive A. Randall, Philip M. Pruna
-
Patent number: 5545184Abstract: A cardiac defibrillator which incorporates the invention hereof includes a multilayer capacitor with a plurality of conductive electrodes and interspersed dielectric layers, each dielectric layer composed of constituents which cause the dielectric layer to exhibit antiferroelectric characteristics. The defibrillator includes a charging circuit for applying to the capacitor an electric field across each dielectric layer that is at least equal to E.sub.f, where E.sub.f is a field value that enables the dielectric layer to transition to a ferroelectric phase. A preferred dielectric material comprises lead, lanthanum, zirconium and titanium, all at constituent values which cause the resulting ceramic material to lie within the antiferroelectric region.Type: GrantFiled: April 19, 1995Date of Patent: August 13, 1996Assignee: The Penn State Research FoundationInventor: Joseph P. Dougherty
-
Patent number: 5391223Abstract: It has been newly determined that in a reaction of an Ag/Pd metallization with Pb from a lead-based ceramics, a maximum solubility of Pb is observed of approximately 14% (atomic percent). By inclusion of an effective amount of Pb in the Ag/Pd metallization, leaching of Pb from a Pb-based ceramic is either reduced or eliminated. Thus, upon firing, the metallization exhibits an equilibration which prevents Pb from being drawn out of the underlying ceramic. Similarly, Ag/Pd metallization shows a maximum solubility of 16 atomic percent for Bi in Bi-based ceramics. Inclusion of an effective amount of Bi in the metallization prevents a Bi leaching from an underlying ceramic.Type: GrantFiled: August 20, 1993Date of Patent: February 21, 1995Assignee: The Penn State Research FoundationInventors: Joseph P. Dougherty, Sea-Fue Wang, Wayne Huebner
-
Patent number: 5124263Abstract: An improved helper cell for growing up stocks of replication incompetent retrovirus vectors is disclosed. The helper cell resists recombination events due to the fact that natural promoters and poly(A) sequences in the helper sequences have been replaced with foreign promoters and poly(A) sequences bearing little or no homology to the vectors. Plasmids containing these modified sequences can still create a helper cell with resulting expression of the needed helper proteins, yet there is much less risk of recombination events in the helper cell. Also disclosed are vectors produced by such helper cells, target cells infected by such vectors, and helper cells which convert vectors so that they can be used with hosts from different species.Type: GrantFiled: January 12, 1989Date of Patent: June 23, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Howard M. Temin, Joseph P. Dougherty
-
Patent number: 4980289Abstract: A recombinant retrovirus vector is disclosed. It is of the type having a normally replication incompetent retrovirus gene sequence with a foreign eukaryotic gene to be expressed. The retrovirus gene sequence is designed so as to be promoter deficient in the right side LTR. The vector can produce progeny virus from helper cells, which progeny can infect a eukaryotic host cell, form a provirus, and express the eukaryotic gene in the host cell. However, the provirus will then be defective in the retrovirus promoter, such that retrovirus RNA is not expressed from the provirus.Type: GrantFiled: April 27, 1987Date of Patent: December 25, 1990Assignee: Wisconsin Alumni Research FoundationInventors: Howard M. Temin, Joseph P. Dougherty
-
Patent number: RE38333Abstract: Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure —OC(R2)2OC(O)X(R)a, wherein R2 independently is H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR3 in which R3 is C1-C12 alkyl; X is N or O; R is independently H, C1-C12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, —O—, —N═, —NR4—, —N(R4)2— or OR3, R4 independently is —H or C1-C8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR3.Type: GrantFiled: May 29, 2002Date of Patent: November 25, 2003Assignee: Gilead Sciences, Inc.Inventors: Murty N. Arimilli, Kenneth C. Cundy, Joseph P. Dougherty, Choung U. Kim, Reza Oliyai, Valentino J. Stella